Abstract: Example embodiments relate to tiltable luminaire joints. One example tiltable joint for a luminaire includes a first joint portion that includes a joint member provided with an outer cylindrical surface section having an axis and opposing bearings aligned with said axis. The outer cylindrical surface section being provided with a first plurality of interengaging surfaces. The tiltable joint also includes a second joint portion that includes a joint housing provided with a pair of axially-aligned receiving surfaces, and an inner cylindrical surface provided with a second plurality of interengaging surfaces configured to interengage the first plurality of interengaging surface. The joint member of the first joint portion is configured for being housed within the joint housing of the second joint portion. Further, the tiltable joint includes first and second shaft portions that extend in alignment with the pair of axially-aligned bearings. Additionally, the tiltable joint includes a fixation means.

Abstract: An input image of a first bit depth in an input domain is received. Forward reshaping operations are performed on the input image to generate a forward reshaped image of a second bit depth in a reshaping domain. An image container containing image data derived from the forward reshaped image is encoded into an output video signal of the second bit depth.

Abstract: The invention relates to the last step of a synthetic process, in which Nomegestrol-acetate of formula (I) is synthesized from 17?-acetoxy-6-methylene-19-norpregn-4-ene-3,20-dione of formula (II) in the presence of Pd/C catalyst and acetic acid in hot ethanolic solution.

Abstract: The invention relates to the last step of a synthetic process, in which Nomegestrol-acetate of formula (I) is synthesized from 17?-acetoxy-6-methylene-19-norpregn-4-ene-3,20-dione of formula (II) in the presence of Pd/C catalyst and acetic acid in hot ethanolic solution.

Abstract: The present invention relates to a new process for the synthesis of compounds of formula (I) (wherein the meaning of R is dimethylamino or acetyl group) using the compound of formula (II) (wherein the meaning of R is dimethylamino or 2-methyl-1,3-dioxolan-2-yl group) as starting material, as well as to the intermediate of the process.

Abstract: The present invention relates to a new stereoselective process for the synthesis of 17(?)-17-acetyl-17-hydroxy-estr-4-en-3-one of formula (I), as well as to the new intermediates of the process. The 17(?)-17-acetyl-17-hydroxy-estr-4-en-3-one (gestonorone) is an important intermediate in the synthesis of the active ingredients having progestogen activity—such as gestonorone capronate and nomegestroi acetate. Formulas (I), (II) and (III).

Abstract: The present invention relates to a new process for the synthesis of compounds of formula (I) (wherein the meaning of R is dimethylamino or acetyl group) using the compound of formula (II) (wherein the meaning of R is dimethylamino or 2-methyl-1,3-dioxolan-2-yl group) as starting material, as well as to the intermediate of the process.

Abstract: The present invention relates to a new stereoselective process for the synthesis of 17(?)-17-acetyl-17-hydroxy-estr-4-en-3-one of formula (I), as well as to the new intermediates of the process. The 17(?)-17-acetyl-17-hydroxy-estr-4-en-3-one (gestonorone) is an important intermediate in the synthesis of the active ingredients having progestogen activity—such as gestonorone capronate and nomegestroi acetate. Formulas (I), (II) and (III).

Abstract: Improved needle bar driving system for sewing machines, that comprises an armshaft rotating with a predetermined speed; a needle bar driving assembly driven by the armshaft and has a needle bar that performs a reciprocating guided linear movement along a substantially vertical axis; a counterweight driving assembly is driven by the armshaft; and a counterweight piston driven by the counterweight driving assembly, and the counterweight piston also performs a reciprocating linear guided movement along an axis parallel to the axis, wherein the movements of the counterweight driving assembly and of the counterweight piston are always opposite to the movement of the needle bar driving assembly and of the needle bar, wherein the combined torque of the counterweight piston and the counterweight driving assembly acting on the armshaft is substantially equal to the combined torque of the needle bar and needle bar driving assembly acting also on the armshaft, but the two torques have opposite direction, whereby the arm

Abstract: Improved needle bar driving system for sewing machines, that comprises an armshaft rotating with a predetermined speed; a needle bar driving assembly driven by the armshaft and has a needle bar that performs a reciprocating guided linear movement along a substantially vertical axis; a counterweight driving assembly is driven by the armshaft; and a counterweight piston driven by the counterweight driving assembly, and the counterweight piston also performs a reciprocating linear guided movement along an axis parallel to the axis, wherein the movements of the counterweight driving assembly and of the counterweight piston are always opposite to the movement of the needle bar driving assembly and of the needle bar, wherein the combined torque of the counterweight piston and the counterweight driving assembly acting on the armshaft is substantially equal to the combined torque of the needle bar and needle bar driving assembly acting also on the armshaft, but the two torques have opposite direction, whereby the arm

Abstract: The invention relates to a new process for the synthesis of high purity 17?-cyanomethyl-17?-hydroxy-estra-4,9-diene-3-one (further on dienogest) of formula (I) from 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V). The invention relates also to the high purity 17?-cyanomethyl-17?-hydroxy-estra-4,9-diene-3-one and pharmaceutical compositions containing that as active ingredient. The pharmaceutical compositions according to this invention contain high purity dienogest of formula (I) in which the total amount of impurities is less than 0.1%, while the amount of 4-bromo-dienogest is under the detection limit (0.02%) as active ingredient or at least one of the active ingredients and auxiliary materials, which are commonly used in practice, such as carriers, excipients or diluents.

Abstract: The invention is directed to a process of preparing substantially pure d-(17?)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3E- and -3Z-oxime isomers, as well as a process for the synthesis of the mixture of isomers and the pure isomers. The invention also relates to substantially pure d-(17?)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene20-yn-3-one-3E-oxime and substantially pure d-(17?)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3Z-oxime isomer. Further aspects of the invention include a composition comprising substantially pure d-(17?)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene20-yn-3-one-3E-oxime or substantially pure d-(17?)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3Z-oxime isomer, and methods of treatment using said compositions.

Abstract: The invention is directed to a process of preparing substantially pure d-(17?)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3E- and -3Z-oxime isomers, as well as a process for the synthesis of the mixture of isomers and the pure isomers. The invention also relates to substantially pure d-(17?)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene20-yn-3-one-3E-oxime and substantially pure d-(17?)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3Z-oxime isomer. Further aspects of the invention include a composition comprising substantially pure d-(17?)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene20-yn-3-one-3E-oxime or substantially pure d-(17?)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3Z-oxime isomer, and methods of treatment using said compositions.

Abstract: The invention relates to a new process for the synthesis of high purity 17?-cyanomethyl-17?-hydroxy-estra-4,9-diene-3-one (further on dienogest) of formula (I) from 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V). The invention relates also to the high purity 17?-cyanomethyl-17?-hydroxy-estra-4,9-diene-3-one and pharmaceutical compositions containing that as active ingredient. The pharmaceutical compositions according to this invention contain high purity dienogest of formula (I) in which the total amount of impurities is less than 0.1%, while the amount of 4-bromo-dienogest is under the detection limit (0.02%) as active ingredient or at least one of the active ingredients and auxiliary materials, which are commonly used in practice, such as carriers, excipients or diluents.

Abstract: A new process is disclosed for the synthesis of racemic or optically pure N-[4-cyano-3-trifluoro-methyl-phenyl]-3[4-fluorophenyl-sulfonyl]-2-hydroxy-2-methylpropionamide. The process includes the formation of several novel intermediates in the synthesis.

Abstract: The invention is directed to a process of preparing substantially pure d-(17?)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3E- and -3Z-oxime isomers, as well as a process for the synthesis of the mixture of isomers and the pure isomers. The invention also relates to substantially pure d-(17?)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene20-yn-3-one-3E-oxime and substantially pure d-(17?)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3Z-oxime isomer. Further aspects of the invention include a composition comprising substantially pure d-(17?)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene20-yn-3-one-3E-oxime or substantially pure d-(17?)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3Z-oxime isomer, and methods of treatment using said compositions.

Abstract: An analytical apparatus for determining the cryolite concentration in a cryolite-alumina electrolysis cell. The apparatus uses a reference electrode comprising a solid oxygen electrolyte tube containing a reference electrode of a cryolite melt supersaturated with alumina. A measuring electrode is combined with such a reference electrode to provide a potential representative of alumina concentration in the alumina electrolysis cell.

Abstract: The invention relates to a process for the removal of contaminating chemical elements from pig-iron, steel and other metals and metal alloys in course of the refining process with oxygen blast, as well as for accelerating hydrometallurgical processes.The essence of the process lies in that quantity of free oxygen radicals and temperature of smelting bath are controlled.

Abstract: A method and apparatus for generating buoyancy power comprising harnessing the buoyant energy contained in hydrogen and oxygen gases which are electrolytically generated under water. A first wheel is submerged in water with a second wheel submerged vertically beneath the first wheel. An endless belt engages and is stretched between the outer surfaces of the first and second wheels and is adapted to rotate the wheels when the belt is driven. A power generator is coupled to one of the wheels and is drivable therewith. As the hydrogen and oxygen gas bubbles are generated at the respective submerged electrodes of an electrolytic generator, the rising bubbles are separately caught in two columns of receptacles along one side of the belt thereby displacing the water from the receptacles and rendering them buoyant. The buoyant receptacles then drive the belt and the first and second wheels thereby causing the power generator to produce an electric current.